Description:

IMAB is the ticker symbol for Immatics N.V., a biopharmaceutical company listed on the New York Stock Exchange (NYSE). The company specializes in the development of innovative T-cell redirecting cancer immunotherapies and neoantigen-based immunotherapies. Immatics aims to harness the power of the immune system to fight cancer by identifying and targeting specific antigens expressed by tumors. Through its proprietary technologies, such as XPRESIDENT and XPAT, Immatics is advancing a pipeline of products designed to improve patient outcomes in various types of cancer.

Data:

Yields: